ADL 5747

Drug Profile

ADL 5747

Alternative Names: ADL-5747; PF-04856881; PF-4856881; PF-4856881 Adolor

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Adolor Corporation
  • Developer Adolor Corporation; Pfizer
  • Class
  • Mechanism of Action Opioid delta receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 18 Jun 2010 Efficacy and adverse events data from a phase IIa trial in Inflammatory pain (osteoarthritis of knee) released by (Adolor Corporation)
  • 27 Jan 2010 Adolor and Pfizer initiate a phase II trial in Pain due to postherpetic neuralgia in USA
  • 30 Oct 2009 Phase-II clinical trials in Pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top